Products

What will AGI do for Azasetron?

This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C17H20ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77HC7URR9Z, chemically known as 2h-1,4-benzoxazine-8-carboxamide, n-1-azabicyclo(2.2.2)oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride but generally known as azasetron, which bears US NIH Compound Identifier 2264. Azasetron most often comes in base and hydrochloride forms. European Medicines Agency schedules Azasetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05642MIG. The term AZASETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). AZASETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azasetron under HS 29349990 and SITC 51579. As of Q4 2014, AZASETRON remains the US FDA Preferred Term for this commodity. Azasetron bears US NLM identifiers UMLS ID C0378974 and NCI Concept Code C73101. SMILES: CLC1CC(C(=O)NC2C3CCN(C2)CC3)C2OCC(=O)N(C2C1)C.